Compare Western Digital Corp (WDC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Digital Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Western Digital Corp trades at $397.28 (market cap $147.23B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Western Digital Corp is far larger — about 14.6× State Street SPDR S&P Biotech ETF's market cap, and Western Digital Corp pays a 0.15% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Western Digital Corp for 37 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| WDC | XBI | |
|---|---|---|
Market Cap | $147.23B | $10.11B |
Volume | 9,341,468 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $746.23 | $169.55 |
52-Week Low | $113.13 | $104.99 |
Typical Hold Time | 37 Days | 38 Days |
Enterprise Value | $146.70B | — |
Dividend Yield | 0.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Digital (WDC) trades at $393.31, down 2.94% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with a P/E of 14.61 and impressive profitability metrics including 71.97% net income margin and 131.02% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $3.56 surpassing the $3.31 estimate. Technical indicators show bearish momentum with the price testing support levels near $387.
WDC presents a compelling value opportunity given its attractive valuation and strong earnings momentum, though near-term headwinds from competitive pressures and technical weakness warrant caution. The 72% analyst buy rating and $647.58 consensus price target suggest significant upside potential for patient investors despite current market concerns about HDD pricing power erosion.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
